Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients

被引:36
|
作者
Brouard, Sophie [2 ]
Le Bars, Alice [3 ]
Dufay, Alexandre [2 ,4 ,5 ]
Gosselin, Morgane [2 ,4 ,5 ]
Foucher, Yohann [2 ,4 ,6 ]
Guillet, Marina [3 ]
Cesbron-Gautier, Anne [7 ]
Thervet, Eric [8 ,9 ]
Legendre, Christophe [8 ,9 ]
Dugast, Emilie [2 ]
Pallier, Annaick [2 ]
Guillot-Gueguen, Cecile [4 ]
Lagoutte, Laetitia [3 ]
Evanno, Gwenaelle [3 ]
Giral, Magali [1 ,2 ,4 ,5 ,10 ]
Soulillou, Jean-Paul [2 ,4 ,5 ]
机构
[1] INSERM, Inst Natl Sante & Rech Med, U643, F-44093 Nantes, France
[2] Inst Transplantat Urol, F-44093 Nantes, France
[3] TcLand Express SA, Nantes, France
[4] Ctr Hosp Univ, Hotel Dieu Nantes, Nantes, France
[5] Univ Nantes, Fac Med, Nantes, France
[6] Univ Nantes, EA Biostat 4275, Nantes, France
[7] Lab HLA EFS Pays Loire, Nantes, France
[8] Hop Necker Enfants Malad, AP HP, Dept Renal Transplantat, Paris, France
[9] Paris Descartes Univ, Paris, France
[10] Nantes Univ Hosp, CICb, Nantes, France
关键词
human; immunology; kidney; tolerance; transplantation; INTERSTITIAL PNEUMONITIS; GRAFT FUNCTION; RECIPIENTS; ALLOGRAFT; SURVIVAL; IMMUNOSUPPRESSION; REJECTION; BIOMARKER; SIGNATURE; HUMANS;
D O I
10.1111/j.1432-2277.2011.01251.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
P>Despite their utility, immunosuppressive treatments have numerous side effects, including infectious complications, malignancies and metabolic disorders, all of which contribute to long-term graft loss. In addition to the development of new pharmaceutical products with reduced toxicity and more comfortable modes of administration, tailoring immunosuppression according to the immune status of each patient would represent a significant breakthrough. Gene expression profiling has been shown to be a clinically relevant monitoring tool. In this paper, we have assessed the overall long-term kidney transplant outcome and attempted to identify operationally tolerant-like patients among recipients with stable clinical status at least 5 years post-transplantation. We thus measured a combination of noninvasive blood biomarkers of operational tolerance in a cohort of 144 stable patients and showed that only 3.5% exhibited a gene expression profile of operational tolerance, suggesting that such a profile can be detected under immunosuppressive therapy but that its frequency is low in kidney transplant recipients when compared with liver transplant recipients. We suggest that a rational approach to patient selection, based on a combination of clinical and biological characteristics, may help to provide a safer method for identification of patients potentially suitable for immunosuppressive drug weaning procedures.
引用
收藏
页码:536 / 547
页数:12
相关论文
共 23 条
  • [21] CD26 Expression on T-Cells and Dipetidyl Peptidase IV (DPPIV) Activity in Plasma as a Complementary Tool to Therapeutic Drug Monitoring (TDM) in Stable Kidney Transplant (KTx) Patients
    Shipkova, M.
    Strobel, S.
    Leicht, S.
    Bolley, R.
    Wilhlem, J.
    Wollmeyer, J.
    Klett, C.
    Olbricht, C.
    Wieland, E.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 668 - 668
  • [22] In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector response to tumor-associated antigens
    Brugiapaglia, Silvia
    Bulfamante, Sara
    Curcio, Claudia
    Arigoni, Maddalena
    Calogero, Raffaele
    Bonello, Lisa
    Genuardi, Elisa
    Spadi, Rosella
    Satolli, Maria Antonietta
    Campra, Donata
    Giordano, Daniele
    Cappello, Paola
    Cordero, Francesca
    Novelli, Francesco
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [23] Implementation of Surgeon-Initiated Gene Expression Profile Testing (Oncotype DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation
    Losk, Katya
    Freedman, Rachel A.
    Lin, Nancy U.
    Golshan, Mehra
    Pochebit, Stephen M.
    Lester, Susan C.
    Natsuhara, Kelsey
    Camuso, Kristen
    King, Tari R.
    Bunnell, Craig A.
    JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (09) : E815 - E820